Is sublingual testosterone an effective and safe option for testosterone replacement therapy?

Sublingual Testosterone for Testosterone Replacement Therapy

Sublingual testosterone is not a standard or recommended formulation for testosterone replacement therapy in current clinical practice, and you should use established FDA-approved formulations instead—specifically intramuscular testosterone cypionate or enanthate (100 mg weekly) or transdermal preparations. 1, 2

Why Sublingual Testosterone Is Not Recommended

Lack of FDA Approval and Guideline Support

• The FDA has not approved sublingual testosterone for treatment of male hypogonadism, and the only FDA-approved oral testosterone formulation (testosterone undecanoate) is explicitly contraindicated for age-related hypogonadism due to demonstrated blood pressure increases and lack of established efficacy. 3, 4
• No major clinical guidelines (Endocrine Society 2018, American College of Physicians 2020, European Association of Urology 2025) recommend or even mention sublingual testosterone as a treatment option for male hypogonadism. 1, 5, 1, 5, 2
• Current guideline-recommended formulations are intramuscular injections (testosterone cypionate/enanthate), transdermal gels/patches, and long-acting testosterone undecanoate injections—sublingual preparations are conspicuously absent from all treatment algorithms. 1, 2

Pharmacokinetic Limitations

• Sublingual testosterone cyclodextrin produces extremely short-lived testosterone peaks (Cmax at 20 minutes) followed by rapid decline to baseline within 2-3 hours, with a half-life of approximately 60-70 minutes, requiring three-times-daily dosing to maintain any therapeutic effect. 6, 7
• This pharmacokinetic profile creates wide fluctuations between supraphysiologic peaks and subtherapeutic troughs throughout each day, which is the exact pattern that guidelines explicitly recommend avoiding because it may increase cardiovascular risk. 1, 6, 7
• The rapid metabolism means patients must dose three times daily (every 8 hours) without fail—missing even one dose results in immediate return to hypogonadal testosterone levels, making adherence extremely challenging. 6, 7

Limited and Outdated Evidence Base

• The only published clinical trials of sublingual testosterone are from 1991-1996 (over 28 years old) and involved small sample sizes (n=51-67 patients) with short follow-up periods (60 days to 6 months)—no long-term safety or efficacy data exist. 8, 6, 9, 7
• These studies demonstrated improvements in sexual function, mood, and lean body mass, but these outcomes are equally or better achieved with FDA-approved formulations that have decades of safety data and far more convenient dosing schedules. 8, 6, 9
• No comparative trials have ever demonstrated sublingual testosterone to be superior to standard intramuscular or transdermal formulations for any clinically meaningful outcome. 8, 6, 9

What You Should Use Instead

First-Line Recommendation: Intramuscular Testosterone Cypionate

• Initiate testosterone cypionate 100 mg intramuscularly once weekly (0.5 mL of 200 mg/mL solution), which provides stable serum testosterone levels and is the most cost-effective option at approximately $156 annually versus $2,135 for transdermal preparations. 1, 10
• Preferred self-injection site is the vastus lateralis (thigh); gluteal injection is acceptable when administered by another person. 1, 10
• Weekly dosing produces more stable testosterone concentrations (400-700 ng/dL) than the traditional 200 mg every 2 weeks regimen, which creates problematic supraphysiologic peaks and subtherapeutic troughs. 1, 10

Alternative: Transdermal Preparations

• Transdermal testosterone gels or patches are appropriate for patients who refuse injections, have cardiovascular risk factors requiring more stable hormone levels, or when cost is not a barrier. 1, 5
• Transdermal preparations provide day-to-day stability and avoid injection discomfort, but cost 13-fold more annually and carry risk of inadvertent transfer to partners or children via skin contact. 1

Mandatory Monitoring Protocol (Regardless of Formulation)

Baseline Assessment

• Obtain two separate early-morning (8-10 AM) fasting total testosterone measurements showing levels <300 ng/dL, plus documented hypogonadal symptoms (decreased libido, erectile dysfunction, fatigue, loss of muscle mass). 1, 2
• Baseline hematocrit (therapy contraindicated if ≥50%), PSA and digital rectal exam in men ≥40 years, and screening for severe untreated obstructive sleep apnea (absolute contraindication). 1, 2, 10

Follow-Up at 3-6 Months

• Measure serum testosterone mid-interval (day 3-4 after weekly injection), targeting 400-700 ng/dL; adjust dose by 25 mg weekly if <350 ng/dL or >700 ng/dL. 1, 10
• Repeat hematocrit and stop therapy immediately if >54%; evaluate for hypoxia/sleep apnea before considering dose reduction and restart. 1, 2, 10
• Repeat PSA and refer to urology if PSA rises >1.4 ng/mL within 12 months, PSA velocity >0.4 ng/mL/year, PSA >4.0 ng/mL, or abnormal digital rectal exam. 1, 2, 10

Annual Monitoring

• Continue yearly hematocrit, PSA, digital rectal exam, and assessment of symptom response (sexual function, energy, quality of life). 1, 2, 10

Absolute Contraindications to Any Testosterone Therapy

• Active prostate cancer or breast cancer, baseline hematocrit ≥50%, untreated severe obstructive sleep apnea, and men actively seeking fertility (testosterone suppresses spermatogenesis—use gonadotropins instead). 1, 2, 10, 4

Critical Safety Warnings

• The FDA required labeling changes in 2015 warning of possible increased risk of myocardial infarction and stroke with testosterone therapy, and some evidence suggests injectable formulations may carry higher cardiovascular risk than transdermals due to greater hormone fluctuations. 1, 4
• Testosterone therapy has been subject to abuse at supraphysiologic doses; if abuse is suspected, check serum testosterone to ensure therapeutic range and counsel on serious cardiovascular and psychiatric adverse reactions. 4
• Long-term safety data beyond 1-2 years are lacking for all testosterone formulations; the ongoing TRAVERSE trial is evaluating cardiovascular outcomes over 5 years. 5, 3